Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Raltitrexed-based chemotherapy as second-line treatment in advanced colorectal cancer: a prospective, multi-center, non-intervention registration study

ABSTRACT: Interventions: Case series:raltitrexed plus Irinotecan Primary outcome(s): Progression Free Survival Study Design: Non randomized control

DISEASE(S): Colorectal Cancer

PROVIDER: 2677366 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A multicenter, prospective, noninterventive, and registration study for raltitrexed and S-1 in the treatment of metastatic colorectal cancer with failure of fluorouracil, oxaliplatin and irinotecan

Project description:Interventions: Case series:raltitrexed with S-1 Primary outcome(s): ORR Study Design: Single arm

| 2691044 | ecrin-mdr-crc

H3K36me3 ChIP-seq in non-treated and raltitrexed-treated UGI-expressing HCT116 cells

Project description:We report ChIP-seq for H3K36me3 that were performed as supplementary experiments to the U-DNA-Seq study (GSE126822). H3K36me3 ChIP-seq was conducted in raltitrexed (RTX) treated or non-treated (NT) HCT116 cells expressing the UNG inhibitor (UGI). We found that the applied RTX treatment did not result in major differences in the genome-wide distribution of the H3K36me3 histone marker. For wider context of the study, see the related publication.

2020-09-20 | GSE153407 | GEO

S-1 and raltitrexed for patients with metastatic colorectal cancer after failure to fluoropyrimidine, irinotecan and oxaliplatin.

Project description:Interventions: experimental group:S-1 and raltitrexed Primary outcome(s): progression - free survival;tumor objective response rate Study Design: Case series

| 2670639 | ecrin-mdr-crc

Phase II study for bevacizumab combined with S-1 and raltitrexed in the treatment of metastatic colorectal cancer resistant to 5-fluorouracil / oxaliplatin /irinotecan

Project description:Interventions: Case series:bevacizumab combined with S-1 and raltitrexed Primary outcome(s): ORR Study Design: Non randomized control

| 2681508 | ecrin-mdr-crc

H3K36me3 ChIP-seq in non-treated and raltitrexed-treated UGI-expressing HCT116 cells

Project description:H3K36me3 ChIP-seq in non-treated and raltitrexed-treated UGI-expressing HCT116 cells

| PRJNA642318 | ENA

The Role of Serum Circulating Tumor DNA (ctDNA) in Recurrence and Efficacy Evaluation of Colorectal Cancer: a Multi-center, Prospective Study

Project description:Interventions: Case series:Nil Primary outcome(s): Serum Circulating Tumor DNA Study Design: Case series

| 2681844 | ecrin-mdr-crc

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

Project description:Irinotecan and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles. The purpose of this study is to evaluate efficacy and safety of irinotecan plus raltitrexed as second-line treatment in advanced colorectal cancer patients.

| 2236701 | ecrin-mdr-crc

Irinotecan plus raltitrexed as second‐line chemotherapy for metastatic colorectal cancer: A retrospective study

Project description: Not available

| S-EPMC11234808 | biostudies-literature

Comparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI).

Project description:PurposeTo compare registration strategies to align arterial spin labeling (ASL) with 3D T1-weighted (T1w) images, with the goal of reducing the between-subject variability of cerebral blood flow (CBF) images.Materials and methodsMulti-center 3T ASL data were collected at eight sites with four different sequences in the multi-center GENetic Frontotemporal dementia Initiative (GENFI) study. In a total of 48 healthy controls, we compared the following image registration options: (I) which images to use for registration (perfusion-weighted images [PWI] to the segmented gray matter (GM) probability map (pGM) (CBF-pGM) or M0 to T1w (M0-T1w); (II) which transformation to use (rigid-body or non-rigid); and (III) whether to mask or not (no masking, M0-based FMRIB software library Brain Extraction Tool [BET] masking). In addition to visual comparison, we quantified image similarity using the Pearson correlation coefficient (CC), and used the Mann-Whitney U rank sum test.ResultsCBF-pGM outperformed M0-T1w (CC improvement 47.2% ± 22.0%; P < 0.001), and the non-rigid transformation outperformed rigid-body (20.6% ± 5.3%; P < 0.001). Masking only improved the M0-T1w rigid-body registration (14.5% ± 15.5%; P = 0.007).ConclusionThe choice of image registration strategy impacts ASL group analyses. The non-rigid transformation is promising but requires validation. CBF-pGM rigid-body registration without masking can be used as a default strategy. In patients with expansive perfusion deficits, M0-T1w may outperform CBF-pGM in sequences with high effective spatial resolution. BET-masking only improves M0-T1w registration when the M0 image has sufficient contrast.Level of evidence1 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2018;47:131-140.

| S-EPMC6485386 | biostudies-literature

Project description:cefepime-zidebactam case series

| PRJNA1174875 | ENA